 |
 |

Fatal Vidarabine Toxicity in a Patient With Normal Renal Function
Linda Van Etta, MD;
John Brown, MD;
Angeline Mastri, MD;
Thomas Wilson, MD
JAMA. 1981;246(15):1703-1705.
 |
 |
| Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings. |
|
 |
 |
PATIENTS experiencing disseminated varicella-zoster infection may have significant morbidity in the form of pain, extreme fevers (temperature 40 °C), rigors, anorexia, malaise, and, rarely, pneumonia, hepatitis, and encephalitis.1 Initially, vidarabine sodium phosphate showed promising results in disseminated herpes zoster with a very low incidence of clinical toxicity.2 More recently, however, several authors have reported cases of possible neurological toxicity. This toxicity was manifested by tremors, dysarthria, confusion, coma, or a combination.3-5 Death occurred in several patients.6 Except for one patient with evidence of renal insufficiency, symptoms developed during administration of the drug.
We have recently observed a patient with disseminated varicella-zoster infection in whom severe, ultimately fatal, CNS symptoms developed 48 hours after completion of an initial three-day course of vidarabine. We report the details of this case of apparent vidarabine CNS toxicity that occurred in the presence of normal renal function in a patient with
. . . [Full Text PDF of this Article]
Author Affiliations
From the Infectious Disease Section, Medical Service, Veterans Administration Medical Center (Dr Van Etta); the Department of Neuropathology, University of Minnesota Medical School (Dr Mastri); and the Departments of Medical Oncology and Neurology (Drs Brown and Wilson), Abbott-Northwestern Hospital, Minneapolis.
Footnotes
Reprint requests to the Infectious Disease Section, Veterans Administration Medical Center, 54th Street and 48th Avenue S, Minneapolis, MN 55417 (Dr Van Etta).
CiteULike Connotea Del.icio.us Digg Reddit Technorati Twitter
What's this?
|